Enveric Biosciences, Inc. (ENVB) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Enveric Biosciences Inc (ENVB) 3-Minute Overview ### 🎯 Layer 1: 30-Second Key Takeaways > **💡 One-Sentence Summary** > > Simply put, Enveric Biosciences is a tiny early-stage biotech betting on psychedelic-inspired neuropsychiatric drugs, so the story is much more about patents, pipeline progress, and funding runway than current revenue. > **📍 Basic Profile** > > Market Cap **$3.44 million** · Pharmaceuticals · NASDAQ NMS - GLOBAL MARKET · Price **$3.65** > **⚡ 3 Things You Should Know** > > 1. 🧪 Pre-revenue biotech reality: This is not a mature drug company with a commercial engine yet—its valuation mostly rests on whether lead programs like EB-003 and related IP can eventually become viable psychiatric treatments. > > 2. ⚠️ Balance sheet looks cleaner than the income statement: Debt is basically zero and liquidity ratios are decent, which helps near-term survival, but profitability is deeply negative and cash burn remains the real issue. > > 3. 📈 Trading is being driven by catalysts and sentiment, not fundamentals: The stock just doubled in a day after psychedelics-policy headlines, which is interesting, but it also tells you this name can move violently on news before the business itself materially changes. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Weak👎 | Net margin **-14.05%**, ROE **-349.1%**, still loss-making | > | Growth Rate | Slow🐢 | 3-year revenue growth **3.35%**, but revenue is not the main value driver here | > | Financial Health | Healthy💚 | Debt-to-equity **0%**, current ratio **4.60** | > | Valuation | [Data unavailable] | PE **[Data unavailable]** due to losses | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Neuroplastogenic small-molecule therapeutics are developed for psychiatric and neurological disorders, with future monetization likely through licensing, partnerships, or eventual drug commercialization. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Drug development / pipeline programs | [Data unavailable] | → | Core value sits in R&D assets rather than operating sales | | Licensing / other revenue | [Data unavailable] | → | Current reported revenue base appears minimal and not very informative | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 20.42% | Below Average | Suggests current revenue base is small and not the reason to own the stock | | Net Margin | -14.05% | Below Average | Still losing money, which is normal for early biotech but risky for shareholders | | ROE | -349.1% | Below Average | Extremely negative returns on equity, often a sign of a tiny equity base plus ongoing losses | --- #### 📈 How's the Growth? **Growth Assessment:** Slowing | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | 3.35%* | [Data unavailable] | Slowing / Low-visibility | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | \*Using 3-year revenue growth data provided. **Growth Quality:** > What’s worth noting is that conventional revenue growth doesn’t tell you much here. For a micro-cap biotech like ENVB, “growth” really means clinical progress, patent wins, and whether management can move programs forward without crushing dilution. In other words, this is pipeline growth, not operating-business growth. --- #### 💰 Financial Health Check **One Sentence:** Think of it like a startup with little debt and some breathing room, but no dependable paycheck—fine today, still dependent on future financing or dealmaking. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 0% debt-to-equity | <60% safe | ✅Safe | | Current Ratio | 4.60 | >1.5 healthy | ✅Safe | | Cash Flow | -$10.58 per share (TTM) | >0 | 🚨Negative | --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $1.71 - 52-Week High: $17.84 - Current: $3.65, Near the low | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | ●(12.1% position) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE [Data unavailable] | 5-year avg [Data unavailable] | [Data unavailable] | | vs Peers | PS 0.09x | Industry avg [Data unavailable] | Looks optically low, but not very meaningful for a loss-making biotech | **What the Current Valuation is Betting On:** > Basically, the market is not paying for present-day earnings. It’s placing a small, speculative option value on ENVB’s intellectual property, lead compounds, and the chance that a favorable psychedelics regulatory backdrop improves partnering or development odds. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-04-20 | Stock surged after Trump’s psychedelics executive order | Positive + suggests sector sentiment can lift ENVB quickly, though this is policy-driven enthusiasm rather than operational proof | | 2026-03-30 | Received U.S. patent for EVM301 series of molecules | Positive + strengthens IP position, which matters a lot for a company whose value is tied to future licensing and defensibility | | 2026-02-25 | Petition against patent withdrawn | Positive + reduces one legal overhang around key patent protection | | 2026-02-20 | Reported EB-003 receptor engagement assay data | Neutral/Positive + encouraging scientific progress, but still far from guaranteed commercial value | | 2026-03-26 | Q4 EPS $(0.50) vs $(57.96) YoY | Mixed + year-over-year loss improved sharply, but biotech EPS can be noisy and should not be over-read | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 20.42% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | -14.05% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | -349.1% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | 3.35%* | [Data unavailable] | [Data unavailable] | → | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | \*Based on provided 3-year revenue growth figure rather than a single-year reported growth rate. --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2024-12-31 | -$2.82 | -$57.60 | -1946.0% Miss 😟 | | 2024-09-30 | -$95.47 | -$43.20 | +54.8% Beat 😀 | | 2024-06-30 | -$100.98 | -$45.00 | +55.4% Beat 😀 | | 2024-03-31 | -$142.29 | -$109.80 | +22.8% Beat 😀 | **Earnings Trend Interpretation:** Three quarters of beats followed by one huge miss tells you reported EPS is volatile and probably distorted by tiny share count effects, one-off items, or the quirks common in micro-cap biotech reporting. In other words, headline EPS surprises here are less useful than funding, IP, and trial milestones. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 6 firms | 85.7% | | Hold | 1 firm | 14.3% | | Sell | 0 firms | 0% | **Target Price:** [Data unavailable] ~ [Data unavailable] (Median [Data unavailable]) **vs Current Price:** [Data unavailable] **Insider Activity:** Net [Data unavailable] in past 3 months > No insider transaction data was provided, so there’s no clean read here. For a stock like this, insider buying would usually be a confidence signal; persistent selling would raise more questions. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Funding Risk:** Negative cash flow per share and ongoing losses mean future capital raises are a real possibility → If this happens, it could lead to shareholder dilution. 2. **Execution Risk:** The company’s value depends heavily on early-stage pipeline progress and IP development → If trial or preclinical results disappoint, the stock could reprice very quickly. 3. **Sentiment Risk:** Recent sharp gains were tied to psychedelics-policy enthusiasm and unusual trading activity → If momentum fades, the stock could give back gains just as fast. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Enveric is a very small speculative biotech focused on neuroplastogenic and psychedelic-inspired therapies for psychiatric and neurological disorders. > > **Key strength:** Its clean balance sheet, patent progress, and ongoing scientific updates give it a credible enough platform to stay in the game. > > **Key risk:** The biggest issue is that this is still a cash-burning, non-profitable micro-cap whose stock can swing wildly on headlines long before fundamentals catch up. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis